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OsteogenesisEmbryoid bodies (EBs) generated fromembryonic stem cells are used to study processes of differentiationwithin
a three dimensional (3D) cell environment. In many instances however, EBs are dispersed to single cell suspen-
sionswith a subsequentmonolayer culture.Moreover,where the 3D integrity of an EB ismaintained, cytokines or
drugs of interest to stimulate differentiation are often added directly to the culture medium at ﬁxed concen-
trations and effects are usually limited to the outer layers of the EB. The aim of this study was to create an
EB model with localised drug and or growth factor delivery directly within the EB. Using poly(DL-lactic
acid-co-glycolic acid) microparticles (MPs) with an average diameter of 13 μm, we have demonstrated control-
lable incorporation of deﬁned numbers of MPs within human ES cell derived EBs, down to 1MP per EB. This was
achieved by coatingMPswith human ES cell lysate and centrifugation of speciﬁc ratios of ES cells andMPs to form
3D aggregates. Using MPs loaded with simvastatin (pro or active drug) or BMP-2, we have demonstrated osteo-
genic differentiation within the 3D aggregates, maintained in culture for up to 21 days, and quantiﬁed by real
time QPCR for osteocalcin. Immunostaining for RUNX2 and osteocalcin, and also histochemical staining with
picrosirius red to demonstrate collage type 1 and Alizarin red to demonstrate calcium/mineralisation further
demonstrated osteogenic differentiation and revealed regional staining associated with the locations of MPs
within the aggregates. We also demonstrated endothelial differentiation within human ES cell-derived aggre-
gates using VEGF loaded MPs. In conclusion, we demonstrate an effective and reliable approach for engineering
stem aggregates with deﬁnable number of MPswithin the 3D cellular structure.We also achieved localised oste-
ogenic and endothelial differentiation associated with MPs releasing encapsulated drug molecules or cytokines
directly within the cell aggregate. This provides a powerful tool for controlling and investigating differentiation
within 3D cell cultures and has applications to drug delivery, drug discovery, stem cell biology, tissue engineering
and regenerative medicine.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
In early development, morphogens are secreted locally to create a
concentration gradient from a source to a sink, which diffuses over
local groups of cells resulting in cells with different phenotypes [1–6].
In this context the location of a cell within this concentration gradient
of the morphogen is an important determining factor for the lineage
commitment towards a speciﬁc phenotype [4,7,8]. For in vitro studies,
when comparing 2D and 3D models, cells often express more speciﬁc
markers and demonstrate morphologies and characteristics that more
closely resemble the native tissue when cultured in a 3D environment
[9]. The orientation of cells within a 3D environment is also important
in the determining of cell morphology, extracellular matrix (ECM)for Biomolecular Sciences, Uni-
44 115 846 7857; fax: +44 115
. Buttery).
NC-ND license.interactions, cell adhesion, differentiation and gene expression as well
as protein level and functionality when compared to 2D monolayer
culture [10–13]. Therefore, a 3D cell culture model can potentially pro-
vide a more reliable approach for applications in tissue engineering and
regenerative medicine [14].
Themulti-cellular aggregates or embryoid bodies (EBs) generated in
the initial stages of differentiation of most embryonic stem cell lines
provide a model that, to some extent, mimics the events during early
development. This in turn can be useful for studying the effects of
small molecules and/or biological agents [15,16] to induce and investi-
gate differentiation [17–20]. However, in many instances after an initial
period of cell aggregation, the resultant EBs are dissociated to single
cell suspensions with subsequent culture of the dispersed cells as
monolayers [21,22]. Other studies have preserved the 3D EB structure
by plating of the whole EBs [23–25].
In addition to methods for controlling cell–cell interactions, growth
factors and drugs are often required to help stimulate differentiation
and typically these are added directly to the culture medium at ﬁxed
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monolayer cell culture, 3D culture models present challenges for deliv-
ery and uptake of growth factors and drugs and in many cases
their effects are restricted to outer regions of the 3D model that is in
direct contact with the culture medium. For drug delivery and tissue
engineering purposes biodegradable polymer microparticles (MPs)
should be capable, ideally, of presenting encapsulated molecules in a
spatiotemporal way that suits the generation of the tissue of interest
[29]. Poly(DL-lactic acid-co-glycolic acid) (PDLLGA) co-polymers are
widely used in tissue engineering and drug delivery. They are available
in a range of molecular weights and lactide to glycolide ratio, which
offers ﬂexibility in controlling the degradation proﬁle and release
kinetics [30–32].
Recent work has demonstrated an improved and more homoge-
neous differentiation of cells within EBs using PDLLGA MPs loaded
with retinoic acid in comparison to the traditional approach involving
retinoic acid supplemented to the culture medium [33]. Although
incorporation of MPs within EBs was successful, the process can be
still variables in term of achieving a reproducible and comparable
incorporation of a deﬁned number of MPs among EBs. In this context,
controlling release and delivery of growth factors within EBs using
polymer MPs can result in an in vitro 3D model with a more reliable
directed differentiation. This might also enable mimicking of morpho-
gen gradients within the developing embryo [33,34].
The incorporation of PDLLGA MPs within EBs can be achieved by a
simple mixing of ES cell–MPs suspensions [33,35]. However, poor cell
attachment to the polymer surface due to polymer hydrophobicity is
a major limitation [36–39]. The latter has been found to be improved
by coating with materials like gelatin or agarose [40], collagen [41]
cadherin [42] and poly-lysine [43]. Improving cell attachment to bio-
materials can be also achieved either by adsorbing or conjugating
ECM peptides or speciﬁc ECM–cell binding sequences on biomaterial
surfaces [44–48] or using biotin–avidin cross-linking [49]. In recent
years there has been an increasing interest in incorporating MPs
within EBs with a focus on approaches to delivering MPs with and
investigation of cellular compatibility and effects on germ layer
differentiation and vasculogenesis [43–45,50,60].
A drawback with many of these studies is the limited control over
the number of MPs incorporated within EBs, potentially resulting in
variability in number of MPs per EB and affecting both amounts of the
drug or cytokine delivered and subsequent cell responses. The incorpo-
ration of a deﬁned number of MPs within the 3Dmulticellular structure
of an EB can provide a model with a focal release of the molecule of
interest from a localised area that can diffuse to the surroundings. This
can provide an efﬁcient differentiation model enhancing lineage com-
mitment from a controlled number of MPs in comparison to the recent
current model(s) using large numbers of MPs.
In this study we demonstrate an effective and efﬁcient approach for
incorporating deﬁnable numbers of PDLLGA MPs within human ES
cell-derived aggregates. Using MPs loaded with simvastatin (pro and
active drugs), bonemorphogenetic protein 2 (BMP-2) or vascular endo-
thelial growth factor (VEGF) we demonstrate localised osteogenic
or endothelial differentiation within the aggregates. This provides a
powerful tool for controlling and investigating differentiation within
3D cell cultures and has applications to drug delivery, drug discovery,
stem cell biology, tissue engineering and regenerative medicine.
2. Materials and methods
2.1. Micro-particle fabrication
Microparticles (MPs) were fabricated from 14% PDLLGA 50:50
(52 kDa, Lakeshore Biomaterials, Inc., USA) in dichloromethane (DCM,
Fisher, UK) by either single or double emulsion methods. In the single
emulsion method, the polymer solution was homogenised in 250 ml
of 0.3% polyvinyl alcohol (PVA, Sigma-Aldrich, UK) using a high speedhomogeniser (Ultra-Turrax, T25 Basic IKA-Werke). The resulting emul-
sion was left stirring at 300 RPM until MPs hardened. In the double
emulsion method, 50 μl of an aqueous solution containing the
molecule of interest (VEGF or BMP-2)was homogenised in the polymer
solution. The resultant primary water in oil (w/o) emulsion was then
homogenised again in 0.3% PVA and the resultant water in oil in water
(w/o/w) double emulsion was left stirring until MPs hardened.
Coumarin-6 [50,51] and/or CellTracker red [35] were used for
labelling MPs and tracking their incorporation within EBs. Labelling
was achieved during MP fabrication with 0.001% Coumarin-6 (Sigma-
Aldrich, UK) and/or 0.02% CellTracker red (Invitrogen, UK).
Loadingwith simvastatin pro-drug (Calbiochem, UK) or simvastatin
active drug (Calbiochem, UK) was done using a single emulsion. The
statins were dissolved in the DCMwith the polymer at 0.5% of the poly-
mer weight. For the cytokines, 0.1% BMP-2, purchased from Professor
Walter Sebald (University ofWürzburg, Germany) or VEGF (PeproTech,
UK) was encapsulated using the double emulsionmethod by dissolving
1 mg of the growth factor in 50 μl of 1% (w/v) human serum albumin
and the process of MP fabrication was continued as described earlier.
Extensive in vitro studies on the controlled release of drugs or cytokines
encapsulatedwithin theseMPs have been performed in aqueous buffers
over 3 weeks using 24 mm plates with 0.4 μm Transwell insert
(Corning, UK). Aliquots of 100 mg of drug loaded PLGA MPs were
suspended in PBS and incubated at 37 °C. The quantiﬁcation of simva-
statin was followed using Agilent 1090 high pressure liquid chromatog-
raphy with UV detector (HPLC-UV). Isocratic separation was fulﬁlled
with C18-Hypersil column (100 × 5 mm, i.d. 5 μm packing, Thermo
Scientiﬁc, UK). The mobile phase included 15% of 1 mM ammonium
acetate adjusted at pH 4.4 and 85% methanol. The ﬂow rate was
maintained at 1 ml per minute at 40 °C and detection was measured
at 238 nm. BCA assay (Sigma-Aldrich, UK) for total protein was used
for BMP-2 quantiﬁcation and we have previously published on the use
of a cell-based assay to measure the release of active BMP2 [52].
2.2. Micro-particle characterisation
The fabricated MPs were subjected to examination for surface mor-
phology via scanning electron microscopy. In brief, MPs were loaded
onto carbon discs (Agar Scientiﬁc, UK) mounted on aluminium stubs
(Agar Scientiﬁc, UK). The MPs were gold-coated using a Balzers SCD
030 gold sputter coater (Balzers Union Ltd., Leichtenstein). Imaging
of the MPs was done using a JEOL 6060L scanning electron microscope
imaging system (JEOL Ltd., Hertfordshire, UK) at 10 kV ionising radia-
tion. Mean diameter and particle size distribution were also investi-
gated using a Coulter LS230 particle size analyser (Beckman, UK). The
particle size distribution was then determined as a function of the
particle diffraction and plotted as a function of volume percentage
(Supplementary Fig. 1).
2.3. Embryoid body formation
Human embryonic stem cells (HUES-7) cultured under feeder free
conditions were dissociated with 0.05% trypsin (Invitrogen, UK) and
suspended inmouse embryonic ﬁbroblast (MEF) cell conditionedmedi-
um consisting of DMEM-F12 (Gibco, UK) supplemented with 15% (v/v)
Knockout serum (Gibco, UK), 1% L-glutamine (2 mM) and 0.01%
2-mercaptoethanol (100 μM) (Sigma-Aldrich, UK), 1% nonessential
amino acids (Sigma-Aldrich, UK), and 8 ng/ml of FGF (Sigma-Aldrich,
UK; 4 ng/ml was supplemented before the medium conditioning with
MEF cells and another 4 ng/ml supplemented before use). Cell suspen-
sions at 1 × 106 cell/ml were transferred to 96 multi-well plate
with V-shaped bottom (Sero-Well, Bibby Sterilin Ltd., UK) at 100 μl
aliquots/well followed by 5 min centrifugation (900 ×g, Sigma 2–16 K).
The culture medium was changed every two days and aggregate/EB
formation was observed between 2 and 4 days after initial seeding and
centrifugation.
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Incorporation of MPs within EBs was accomplished by coating MPs
with HUES-7 cell lysate. In brief, using a haemocytometer, 5 × 105
MPs were suspended in 1 ml PBS containing HUES-7 cell lysate from
1 × 106 cell. The ﬁnal suspension was then mixed gently and left on a
roller mixer for 2 h before use. Aggregation was performed in a 96
multi-well plate with V-shaped bottom (Sero-Well, Bibby Sterilin Ltd.,
UK) as described above at 50:1 cell to MP ratio.
Using Nikon stereomicroscope SMZ 1500which allowed bright ﬁeld
as well as ﬂuorescent image capturing, coumarin-6 labelled MPs
appearing in greenwere counted visually for each cell pellet. The distri-
bution and localisation of PLGA MPs within multi-cellular EB model
were studied using confocal microscopy (Leica SP2). Image analysis
and Z stacking over a 10 μm optical section was accomplished using
Velocity 5 software.
Experimental groups included EBs with MPs loaded with either
BMP2, simvastatin pro-drug or active drug. Control groups included
EBs with blank MPs or EBs without MPs.
Cell culture medium used for experimentation was MEF cell condi-
tioned medium, without any other factors other than released from
the MPs as described earlier.
2.5. Real time QPCR for osteocalcin
All cultures were lysed and RNA extracted using a Qiagen RNeasy
mini kit (Qiagen, UK). RNA was quantiﬁed using a Nanodrop (Labtech,
UK). Samples were reverse transcribed into cDNA using superscript III
system (Invitrogen, UK). In brief, this included, mixing of 1 μl of
10 mM dNTP (Roche Applied Science) and 1 μl of random hexamer
(250 ng/μl) (Invitrogen, UK) in addition to 11 μl of molecular biology
grade water (Sigma-Aldrich, UK) containing 100 ng total RNA. The re-
actionmix was then transferred to a thermocycler (PX2) and incubated
at 65 °C for 5 min to allow denaturation before quenching on ice for
1 min. Reaction Master Mix consisting of 4 μl of the ﬁrst strand buffer,
1 μl of DTT, 1 μl of RNase-OUT and 1 μl of superscript III enzyme was
prepared and added to the reaction mix after cooling of samples. With
a ﬁnal volume of 20 μl of sample, reverse transcription was started by
incubation in thermo-cycler for 5 min at 25 °C then 60 min at 55 °C
and ﬁnally the reaction was ended by heating for 15 min at 70 °C.
qPCR was followed using Taqman Probes for osteocalcin and GAPDH
(Applied Biosystems, UK).
2.6. Osteocalcin ELISA
Cell culture supernatant from different groups was ﬁrst puriﬁed
using special protein collection column (Millipore, UK). Samples were
spun for 30 min (14,000 ×g, Sigma 1-16Ke) then follow through
discarded and puriﬁed samples were collected from the membrane.
Quantiﬁcation of OCN was done using an ELISA kit from Bender
Medsystems, Austria. 100 μl of distilled water plus 25 μl of each
sample were added to a separate micro-plate wells. These were pre-
coated with monoclonal mouse antibody against human OCN and also
contained a lyophilised HRP-conjugate which is murine anti-human
OCN monoclonal antibody. Incubation continued for 2 h at room tem-
perature before washing. Then a 100 μl/well of substrate solution
(tetramethylbenzidine) was added to samples followed by incubation
for 15 min at room temperature (protected from light). Finally, 100 μl
of a stop solution consisting of 1 M phosphoric acid was added and
the optical density (OD) was measured at 450 nm using multimode
micro-plate reader (Tecan Inﬁnite 200, Switzerland). The experiment
was repeated two times with a total of six replicates. Statistical analysis
for sample replicates was followed using GraphPad InStat version 3.0
(GraphPad Software Inc.). Data analysis used the unpaired t test for
parametric data sets and results were considered signiﬁcant whenP b 0.05 (*), very signiﬁcant when P b 0.01 (**) and extremely signiﬁ-
cant when P b 0.001 (***).
2.7. Immunostaining
Staining for OCN and/or RUNX-2 was performed on samples ﬁxed
in a 4% (w/v) solution of para-formaldehyde (Sigma-Aldrich, UK) in
PBS for 15 min then washed with PBS for 5 min. A mouse staining
kit (R&D, UK) was used for detecting OCN staining and a goat staining
kit was used for Runx-2 (R&D, UK). Endogenous peroxidase was
exhausted by incubation with 3% hydrogen peroxide in PBS for
5 min. Samples were then washed with PBS buffer for 5 min before
incubation with serum blocking for 15 min. Incubation was followed
with avidin blocking reagent for another 15 min then rinsed with PBS
buffer and drained from excess moisture. The latter step was repeated
with biotin blocking reagent. Samples were then incubated overnight
(2–8 °C) with the primary antibody solution (10 μg/ml) which was
goat anti-human RUNX-2 antibody (R&D UK) or murine anti-human
OCN antibody (R&D UK). On the following day, samples were rinsed
with PBS for 15 min then drained from excess moisture before incuba-
tion with the biotinylated secondary antibody for 60 min. This was
followed by washing with PBS for 15 min and drained samples were
then incubated with high sensitivity streptavidin-horse radish peroxi-
dase conjugate (HSS-HRP) for 30 min. A brief PBS washing steps for
2 min was then followed by incubation with 3,3-diaminobenzidine
(DAB) chromagen solution for up to 20 min. Then after, samples were
washed with distilled water and mounted with ProLong Gold antifade
reagent with DAPI (Invitrogen, UK) and stored in the dark at 4 °C until
microscopic examination. Technical controls were always used to
exclude non-speciﬁc binding of the secondary antibody.
2.8. Histology
Alizarin red (AR) staining for calcium andmatrixmineralisationwas
donebyﬁrstwashing sampleswith PBS followed byﬁxation in 4% (w/v)
para-formaldehyde (Sigma-Aldrich, UK) in PBS for approximately
30 min. A second washing step with deionised water was followed
before staining with 1% AR (w/v) (Sigma-Aldrich, UK) in deionised
water, pH 4.2 for 5 min at room temperature. The cell preparations
were washed ﬁve times with deionised water until the water became
clear.
Demonstration of collagenwas done by stainingwith a 0.1% solution
of picrosirus red in saturated aqueous picric acid (VWR, UK). Samples
were incubated at room temperature for 40 min before brief washing
with water then industrial methylated spirit and ﬁnally mounting in
PBS:glycerol (1:1) before imaging.
3. Results
3.1. 3D model of hES cell derived EBs containing MPs
Incorporation of PDLLGA MPs within the multicellular structure of
human ES cell-derived EBswas done by forced aggregation via centrifu-
gation. Different cell to MP ratios ranging from 50:1 to 3000:1 were
investigated. The incorporation of a deﬁned number of MPs within the
cell pellet was successful as shown in Table 1. HUES-7 cells have no
afﬁnity toward PDLLGA MPs as suggested by the observation, where
despite the presence ofMPswithin the cell pellets on day zero of aggre-
gation, by day two most of the MPs had been expelled from the EBs.
Only sporadic replicates revealed a few MPs retained on the periphery
of the EBs on day 4 as shown in Fig. 1(A). This kind of sporadic,
unpredictable aggregation will not be of value in establishing a reliable
3Dmodel of HUES-7 cell aggregate with PDLLGAMPs. Marked improve-
ment with MP incorporation within hES cell-derived EBs was achieved
by suspending theMPs in HUES-7 cell lysate solution prior to the aggre-
gation process. Results from this approach appeared to be successful
Table 1
The incorporation of a deﬁnable number of HUES-7 cell lysate coated PDLLGA MPs with
HUES-7 cell pellet at different cell to MPs ratio.
The cell/MP ratio Predicted MP number within
3 × 103 cell pellet
Actual MP number within
3 × 103 cell pellet
50 to 1 60 59 (±7.5)
100 to 1 30 23 (±1)
300 to 1 10 10 (±1.6)
500 to 1 6 5 (±0.6)
1000 to 1 3 4 (±0.3)
3000 to 1 1 2 (±0.4)
Values of actual MP incorporation were expressed asmean ± SEM from 5 to 9 replicates.
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shown in Fig. 1B; these MPs remained within EBs until day 21 as
conﬁrmed in Fig. 2A.
Time lapse microscopy imaging for HUES-7 derived EBs between
day two and three post aggregation revealed dynamic movement
within the aggregate as shown in the Supplementary movie (S2).
3.2. PDLLGA MPs as a release model for EBs
The application of PDLLGA MPs as a release model within EBs was
tested using PDLLGA MPs loaded with CellTracker red. The results were
consistentwith time lapse video observations described above, with dy-
namic movement within the EB structure (Fig. 2A). MPs appeared to be
located around the centre of the EB until day 7 (Fig. 2A1and A2) then
became more dispersed throughout the EB by day 14 (Fig. 2A3). MPs
remained within the EBs until the end of the study on day 21
(Fig. 2A4). The distribution of the MPs within EBs was conﬁrmed from
reconstructed z-stack images collected by confocal microscopy (Fig. 2B
and the Supplementary movies S3 and S4). There was an interesting
pattern of release and diffusion of the encapsulated CellTracker redFig. 1. Representative microscopic image for HUES-7 EBs/PDLLGA MPs aggregate with arrow
zero (MPs within the cell pellet) and day 2 with most of the MPs expelled out of the EB follo
coated PDLLGA MP integration within EB multicellular structure, these MPs were retained wfrom the MPs within the multi-cellular EB structure as shown in
Fig. 2A. The diffusion of the red ﬂuorescence was limited within the EB
structure on day 4 and became more uniform by days 7, 14 and 21
with whole EB showing red ﬂuorescence.
3.3. Simvastatin and /or BMP-2 loaded MP model
A 3D model of HUES-7-derived EBs containing PDLLGA MPs loaded
with simvastatin pro-drug or simvastatin active drug or BMP-2 was
tested for osteogenic differentiation for up to 21 days in culture. Exam-
ples of release proﬁles of the encapsulated molecule(s) can be seen in
Supplementary Fig. 5.
3.3.1. Osteocalcin gene expression
Real timequantitative PCRwas used tomeasure the difference in the
gene expression of OCN (late marker for osteogenesis) relative to
GAPDH gene expression. The relative OCN expression was quantiﬁed
on days 7, 14 and 21 as fold change in relation to a reference group of
day 21 EBs without MPs. As shown in Fig. 3A, there was a comparable
up-regulation in OCN expression on day 21 by around 2 fold with MPs
loadedwith each one of the following; simvastatin prodrug, simvastatin
active drug and BMP-2. EBs containing blank MPs showed a 1.57 fold
increase in OCN expression on day 21; however OCN expression was
detected on day 21 but not days 7 and 14 with EBs without MPs and
EBs containing blank MPs.
3.3.2. Osteocalcin protein release
The ELISA OCN protein release assay revealed similar but modest
increases in the level OCN secreted into the culture medium (Fig. 3B );
simvastatin pro-drug 2.44 (±0.07 ng/ml), simvastatin active drug 2.36
(±0.032 ng/ml) and BMP-2 2.42 (±0.04 ng/ml). These increases were
signiﬁcantwhen compared against control experiments which included
EBs containing MPs without any loaded drugs or cytokines and particu-
larly for EBs without MPs.s referring to the MPs. A) — The incorporation of the PDLLGA MPs within EBs from day
wed by day 4 showing EBs with or without superﬁcially attached MPs. B) — Cell lysate
ith EBs between day zero and day 7. Scale bar equals to 500 um.
Fig. 2. Representative microscopic images for HUES-7 EBs/PDLLGA MP aggregate. A) HUES7 cell lysate treated MPs, A1–A4 are bright ﬁeld images (top) and ﬂuorescent images for
MPs labelled with CellTracker red (bottom). Cell number per EB was 3 × 103 cells per well with 50:1 cell–MPs ratio. MPs can be seen ﬂuorescing with CellTracker red on days 4
(A1), 7 (A2), 14 (A3) and 21 (A4). Finally, B) Confocal microscopy images (40×) for HUES-7 EBs stained with DAPI nuclear stain appear with PDLLGA MPs labelled with CellTracker
red at different time points (B1 — day 2, B2 — day 7, B3 — day 14 and B4 — day 17).
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3.3.3.1. RUNX2. The presence of RUNX-2 (early osteogenic marker) in
EBs containing MPs loaded with simvastatin (pro or active drug) and/
or BMP-2 was compared against control group of EBs containing blank
MPs and/ or EBswithoutMPs. Results revealed a comparable weak pos-
itive staining (light brown) with both control groups containing blank
MPs or devoid fromMPs on day 7. Amost and comparable level of stain-
ingwas seenwithin EBs containingMPswith either form pro and active
drug forms of simvastatin (see the Supplementary Fig. 6).
3.3.3.2. Osteocalcin. Results of OCN immunostaining was consistent
with observations on OCN gene expression with no evidence of stain-
ing on day 7 (Fig. 4A), however, weak positive staining was evident
on day 21 in EBs without MPs and similarly within EBs containing
blank MPs as seen in Fig. 4B. More intense staining for OCN was evi-
dent within EBs containing MPs loaded with BMP2 (Fig. 4B3) and/or
simvastatin active drug (Fig. 4B3) and/or simvastatin prodrug
(Fig. 4B5). Furthermore, MPs could be readily identiﬁed within EBs
and it was possible to locate zones of positive staining for OCN around
MPs embedded within EBs (Supplementary Fig. 7).
3.3.3.3. Histochemical staining for collagen and calcium/mineral deposi-
tion. Collagen formation was investigated by picrosirius red staining,
which can be used to distinguish collagens. All groups of EBs showed
evidence for picrosirius red staining (Fig. 5A) within the EBs. Staining
for picrosirius red appeared more intense and homogeneous in day
21 EBs with MPs containing BMP-2, simvastatin active drug or simva-
statin pro-drug.
Calciumandmineralisationwithin EBswere assessed byAlizarin red
staining and there was no evidence of staining in any of the groups
under test on day 14 (Fig. 5B). By day 21 small areas of staining were
evident in EBs without MPs and EBs with blank MPs (Fig. 5B1a and
B2a). Appreciably more Alizarin red staining was seen in EBs with
MPs containing BMP-2 (Fig. 5B3a), simvastatin active drug (Fig. 5B4a)
or simvastatin pro-drug (Fig. 5B5a) and was similar between each
group in terms of distribution and intensity of staining.3.4. VEGF loaded MPs
There was no evidence of immunostaining for CD31 PECAM
revealed in any of the EB groups on day 7 (Fig. 6). By day 14 there
was obvious staining for CD31 only in EBs VEGF MPs, which became
more prominent by days 21 and 28 and eventually spreading through-
out the whole EB.
4. Discussion
In this study we demonstrate an effective and efﬁcient approach for
incorporating deﬁned numbers of MPs within human ES cell derived
aggregates. Moreover, by incorporating simvastatin pro or active drug
or BMP2 or VEGF into theMPswe show localised osteogenic and vascu-
lar differentiationwithin the cellular aggregates. This provides a power-
ful tool for controlling and investigating differentiation within 3D cell
cultures and has applications for drug delivery, drug discovery, stem
cell biology, tissue engineering and regenerative medicine.
In recent years there has been much interest in developing 3D cell
models with controlled release of cytokines or drugs from MPs within
those models. Important considerations for creating successful 3D
models require attention to the incorporation of MPs within the multi-
cellular EB structure and should enable reliable distribution and a
release pattern of the encapsulated molecule of interest in a sustained
andpredictablemanner. Ferreira, Squier, Park, Choe, Kohane, and Langer
in 2008 incorporated MPs successfully within human ES cell-derived EB
by suspending MPs as mg/ml preparation in culture medium with ES
cells before centrifugation [34]. Rotary orbital culture has also been
used for incorporating MPs within EBs [33,35]. In a more recent study,
Bratt-Leal, Carpenedo, Ungrin, Zandstra, and McDevitt in 2011 demon-
strated a more efﬁcient incorporation of MPs within EBs using a forced
aggregation method and directly when compared against rotary orbital
culture [40].While previous studies have reported successful incorpora-
tion ofMPs into EBs, the level of control of numbers ofMPs has been var-
iable, ranging from aminimumof less than 100MPs/EB and amaximum
of up to 600 MPs per EB. Such variability is likely to affect both amounts
of the drug or cytokine delivered and subsequent cell responses. The aim
Fig. 3. A) — Relative expression of OCN to GAPDH in HUES-7-derived EBs containing
MPs loaded with either 0.1% BMP-2, 0.5% simvastatin prodrug or active drug or blank
MPs. Gene expression was quantiﬁed on days 7, 14, 21 and presented as fold change
in relation to reference of day 21 EBs devoid from MPs as mean ± SEM (n = 2 and
r = 3). B) Secreted human OCN protein levels in HUES-7-derived EBs on day 21. Results
expressed as Mean ± SEM of 6 determinations. Differences considered signiﬁcant
(*) when P b 0.05, highly signiﬁcant (**) when P b 0.01 and extremely signiﬁcant
(***) when P b 0.001.
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within EBs, down to 10 or fewer MPs per EB and thereby provide mini-
mal disruption to EBs integrity and cell interactions and enable better
investigation of the effects of low, local concentrations of the released
molecule of interest.
One of the challenges for introducing PDLLGA MPs into cellular
aggregates is the hydrophobicity of the polymer surface and its poor
wettability, which can hinder cell attachment [36]. Furthermore, cells
within the early embryo can be highly mobile [53]. Cell mobility and
MP movement were seen in this study and offer an explanation for
initial failed attempts to achieve precise control in terms of MP number
within ES cell pellet pre-aggregation and loss of MPs from within EBs
post aggregation. Improved cell interaction and attachment to polymer
surfaces can be achieved by changing surface roughness using ethanol
or sodium hydroxide [36,54] or via coating with different materials
like collagen, gelatine, and agarose [33,35,40,41]. However, variability
related to the coatingmaterial has been reported [40]. For these reasons
in the present work, marked improvement of MP incorporation withEBs was achieved following coating of MPs with hES cell lysate.
Although coating could have an inﬂuence on the release proﬁle of the
molecules of interest, on the other hand the results demonstrated accu-
racy for the incorporation of PDLLGA MPs within EBs down to one MP
per EB. The model was stable with MPs still detectable at different
regions within the EBs throughout the 21 days of the study conﬁrming
retention of the incorporated MPs and the overall reliability of this
deliverymethod. Themechanisms contributing to improved incorpora-
tion and retention of MPs within EBs by prior coating with hES cell
lysate remains to be investigated, although using lysate from the same
cell source as those contributing to the formation of the cell aggregate
might improve compatibility.
Following on from creating a reliable and controllable incorporation
of PDLLGA MPs within hES cell derived EBs, the release proﬁle of the
CellTracker red MPs and progressive distribution of the dye throughout
EBs over time demonstrated the efﬁcacy of themodel for future applica-
tions with controlled release bioactive molecules. This also facilitated
demonstration of our approach to deliver drugmolecules and cytokines.
The release pattern started with an initial burst followed by a decline
phase which entered a steady state release with both forms of simva-
statin. Unlike the statins, BMP-2 release started with an initial burst
then followed by a steady state release. In this study we chose to inves-
tigate delivery of simvastatin pro- and active drugs and BMP2 as
known inducers of osteogenesis [55] and also VEGF as an inducer of
vasculogenesis [56]. The efﬁcient diffusion of CellTracker red can be
facilitated by a combined effect from an initial burst release and highly
mobile MPs within an EB which can add to the model reliability for
efﬁcient delivery of the molecule of interest.
Induction of osteogenic differentiation involves Runx-2 up-regulation,
which is a key transcription factor during osteogenesis [57–59]. Runx-2 is
believed to be an upstream regulator forOsterix [60] and is also responsi-
ble for regulating ALP, OCN, osteopontin, collagen-I and BSP expression,
however its expression is transient [59,61–66]. OCN tends to show
up-regulation associated with ECM formation and mineral deposition
and is considered a comparatively late marker of end stage osteogenic
differentiation [67]. Therefore OCN was considered a useful marker for
evaluating the 3D-MPs model for osteogenesis and to also demonstrate
stability of the model over 21 days. Results in this study showed a time
dependent expression of OCN with the highest level seen at day 21 and
was consistent and comparable for simvastatin pro- and active drugs
and BMP-2, with a negligible expression in EBs without MPs or with
blank MPs. Staining for Runx-2 protein suggested a higher expression
in EBs containing PDLLGA MPs loaded with either forms of simvastatin,
however a weaker expression was noticed with the BMP-2 group and
could relate to an earlier expression of this temporally expressed early
marker during osteogenesis. Osteogenic differentiation was further con-
ﬁrmed by OCN protein release detected by OCN ELISA and these results
were consistent with the OCN gene expression data. OCN was also
detected within the EBs by immunostaining and robust staining was
seen in EBs containing MPs loaded with simvastatin pro or active drugs
or BMP-2, with localised zones of staining associated with MPs within
the EBs. Consistent ﬁndings were also seen for the major ECM protein
(collagen). The latter stages of osteogenesis typically involve matrix
mineralisation [68] which was not evident in this study until day 21
with appreciably higher levels of calcium deposition and suggested
mineralisation within EBs containing MPs loaded with either forms of
simvastatin or BMP-2.
From these studies it was noted that while the best evidence for os-
teogenesis was supported from observations using MPs releasing
known osteogenic drugs and cytokines there was still evidence of oste-
ogenesis within EBs containing blank MPs particularly when compared
with EBs without MPs. Several studies have reported important contri-
butions from surface chemistry and micro-topography on osteogenesis
[69–74] and Scaglione, Braccini, Wendt, Jaquiery, Beltrame, Quarto, and
Martin in 2006 demonstrated osteogenesis on a 3D ceramic scaffold in
the absence of deﬁned osteo-inductive molecules [75]. This together
Fig. 4. Immunostaining for OCN in day 7 EBs (A1–A5) and day 21 EBs (B1–B5), positive results appear in brown, samples were counterstained with DAPI nuclear staining (appeared
with blue ﬂuorescence) with arrows showing MPs. EBs without MPs (A1 and B1) and EBs with blank MPs (A2 and B2). BMP-2 loaded MPs (A3 and B3), simvastatin active drug MPs
(A4 and B4) and simvastatin pro-drug loaded MPs (A5 and B5).
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Ewith the physical presence of the polymer MPs could help explain the
small amount of osteogenesis seen within EBs containing MPs without
any drug molecules or cytokines.Fig. 5. Representative microscopy images of EBs stained with picrosirius red (left panels) on
on day 14 (B1–B5) and day 21(B1a–B5a). Positive results appear in bright red staining; (A1 a
MPs; (A3 and B3) simvastatin active drug MPs and; (A5 and B5) simvastatin pro-drug MPsAs a further example of the applications of this MP delivery method
we also demonstrated differentiation of endothelial cells, based on
CD31 PECAM, within EBs containing VEGF MPs. Related on-goingday 14 (A1–A5) and day 21 (A1a–A5a) and EBs stained with Alizarin red (right panels)
nd B1) EBs without MPs; (A2 and B2) EBs with blank MPs; (A3 and B3) EBs with BMP-2
.
Fig. 6. Representative brightﬁeld and ﬂuorescencemicroscopy images of days 7, 14, 21 and 28HUES-7 EBs stainedwith CD31 PECAM. Positive results appear in red. A— EBswithoutMPs.
B — EBs with blank MPs. C — EBs with 0.1% VEGF MPs.
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Ework is exploring approaches to engineer cell aggregates to containMPs
with different drugs/cytokines and to facilitate co-ordinated delivery of
multiple signals within 3D cell aggregates.
5. Conclusion
Work presented in this study succeeded in establishing an effective
method for introducing and retaining deﬁnable numbers of MP human
ES cell-derived 3Dmulticellular aggregates.We also demonstrate the ca-
pacity for these MPs to deliver drug molecules and cytokines directly
within the cellular aggregates and as speciﬁcally investigated here
using simvastatin, BMP2 and VEGF facilitating localised osteogenic or
vasculogenic differentiation. This approach can help to overcome the
limitations associated with the many current models of ensuring efﬁ-
cient directed delivery of drugs or cytokines to andwithin 3D cell culturemodels and has wide applications in drug delivery and regenerative
medicine.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jconrel.2013.02.029.
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